HPTN Publications

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim J, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, et al . Prevention of HIV-1 infection with early antiretroviral therapy. NEJM. 2011, 365: 493-505 PMCID: 3200068
Cohen MS, Mastro TD, Cates W Jr . Universal Voluntary HIV Testing and Immediate Antiretroviral Therapy. Lancet. 2009, 373: 1077 (Published comment)
Cohen MS, McCauley M, Gamble TR . HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012, 7: 99-105 PMCID: 3486734
Cohen, MS, McCauley, M, Sugarman, J . Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. Clin Trials. 2012, 9: 340-7 PMCID: 3486723
Coletti A, Heagerty P, Sheon A, Gross M, Koblin B, Metzger D, Seage G . Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine trials. J Acquir Immune Defic Syndr. 2003, 32: 161-9
Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, Koblin B, Chesney M, Vittinghoff E . Longitudinal patterns of methamphetamine, popper (Amyl Nitrite), and the cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health. 2005, 82: i62-i70
Colfax G, Vittinghoff E, Husnik MJ, McKirnan D, Buchbinder S, Koblin B, Celum C, Chesney M, Huang Y, Mayer K, Bozeman S, Judson FN, Bryant KJ, Coates TJ, EXPLORE study team . Substance Use and Sexual Risk: A Participant- and Episode-level Analysis among a Cohort of Men Who Have Sex with Men. Am J Epidemiol. 2004, 159: 1002-12
Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, Musoke P, Stranix-Chibanda L, Chetty V, Fawzi W, Nakabiito C, Msweli L, Kisenge R, Guay L, Mwatha A, Lynn D, Eshleman S, Richardson P, George K, Andrew P, Mofenson L, Zwerski S, Maldonado Y . Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012, 379: 221-8 PMCID: 3539769
Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, Eaton JW, Hauck K, Smith P, Griffith S, Moore A, Donnell D, Vermund SH, Fidler S, Hayes R, Fraser C; HPTN 071 PopART Study Team . HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014, 9: e84511
Corneli A, Pettifor A, Kamanga G, Golin C, McKenna K, Ou SS, Hamela G, Massa C, Martinson F, Tharaldson J, Hilgenberg D, Yu X, Chege W, Hoffman I; HPTN 062 study team, Hoffman I, HPTN 062 study team . HPTN 062: A Feasibility and Acceptability Pilot Intervention to Reduce HIV Transmission Risk Behaviors Among Individuals with Acute and Early HIV Infection in Lilongwe, Malawi. AIDS Behav. 2014, 18: 1785-800
Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH . HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. J Clin Microbiol. 2014, 52: 115-21
Cousins MM, Konikoff J, Sabin D, Khaki L, Longosz AF, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Kobin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH . A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation. PLoS One. 2014, 9: e101043
Cousins MM, Laeyendecker O, Beauchamp G, Brookmeyer R, Towler WI, Hudelson SE, Khaki L, Koblin B, Chesney M, Moore RD, Kelen GD, Coates T, Celum C, Buchbinder SP, Seage GR, Quinn TC, Donnell D, and Eshleman SH . Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One. 2011, 6: e27211 PMCID: 3206918
Cousins MM, Ou SS, Wawer MJ, Munshaw S, Swan D, Magaret CA, Mullis CE, Serwadda D, Porcella SF, Gray RH, Quinn TC, Donnell D, Eshleman SH, Redd AD . Comparison of a high-resolution melting assay to next-generation sequencing for analysis of HIV diversity. J Clin Microbiol. 2012, 50: 3054-9 PMCID: 3421787
Crowell TA, Hardick J, Lombardi K, Parker Z, Kokogho A, Amusu S, Odeyemi S, Ivo A, Baral SD, Nowak RG, Adebajo S, Charurat ME, Ake J, Gaydos CA, TRUST/RV368 Study Group . Asymptomatic lymphogranuloma venereum among Nigerian men who have sex with men. Sex Transm Infect. 2018, 94: 578-581
Cunha CB, Friedman RK, de Boni RB, Gaydos C, Guimarães MR, Siqueira BH, Cardoso SW, Chicayban L, Coutinho JR, Yanavich C, Veloso VG, Grinsztejn B . Chlamydia trachomatis, Neisseria gonorrhoeae and syphilis among men who have sex with men in Brazil. BMC Public Health. 2015, 15: 686
Cunningham S, Ank B, Lewis D, Wei L, Wantman W, Dileanis J, Jackson JB, Palumbo P, Krogstad P, and Eshleman SH . Performance of the Applied Biosystems ViroSeq HIV-1 Genotyping System for analysis of HIV-1 in pediatric plasma samples. J Clin Microbiology. 2001, 39: 1254-7
Curlin ME, Cassis-Ghavami F, Magaret AS, Spies GA, Duerr A, Celum CL, Sanchez JL, Margolick JB, Detels R, McElrath MJ, Corey L . Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS. 2011, 25: 153-8 PMCID: 3057418
Dai JY, Gilbert PB, Mâsse BR . Partially hidden Markov model for time-varying principal stratification in HIV prevention trials. J Am Stat Assoc. 2012, 107: 52-65 PMCID: 3649016
Daley T . Impact of traditional healers on clinical research in Tanzania. Research Practitioner. 2006, 7: 216
Daniels J, Komárek A, Makusha T, Van Heerden A, Gray G, Chingono A, Mbwambo JK, Coates T, Richter L . Effects of a community intervention on HIV prevention behaviors among men who experienced childhood sexual or physical abuse in four African settings: findings from NIMH Project Accept (HPTN 043). PLoS One. 2014, 9: e99643
DeMaria, Jr, A, Kunches L, Mayer K, Cohen C, Epstein P, Werner B, Day J, DeCristofaro J, Landers S, Tang Y, Coady W, and the Massachusetts gp160 Working Group . Immune Responses to a Recombinant Human Immunodeficiency Virus Type 1 (HIV-1) gp160 Vaccine Among Adults with Advanced HIV Infection. J Hum Virol. 2000, 3: 182-92
Des Jarlais DC, Marmor M, Friedmann P, Titus S, Aviles E, Deren S, Torian L, Glebatis D, Murrill C, Monterroso E, Friedman SR . HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health. 2000, 90: 352-9
Dhawan D, Mayer KH . Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis. 2006, 193: 36-44 PMID: 16323129
Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, Donnell DJ, Mannheimer S, Holtz TH, Grant RM, Boily MC . Predicted Effectiveness of Daily and Non-Daily PrEP for MSM Based on Sex and Pill-Taking Patterns from HPTN 067/ADAPT. Clin Infect Dis. 2019
Donnell D, Hughes J, Fleming TR . Challenges in the Design of HIV Prevention Trials in the United States. JAIDS. 2010, 55: S136-S140 PMCID: 3298818
Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR . Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. J Acquir Immune Defic Syndr. 2013, 63: S130-4
Donnell DJ, Hall I, Gamble T, Beauchamp G, Griffin AB, Torian LV, Branson B . Use of HIV Case Surveillance System to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. Open AIDS J. 2012, 6: 122-30 PMCID: 3462339
Dyer, T. V., Khan, M. R., Regan, R., Harawa, N. T., Nelson, L. E., Wilton, L., Wang, L., Peng, L., Ou, S. S., Shoptaw, S. . Differential Patterns of Risk and Vulnerability Suggest the Need for Novel Prevention Strategies for Black Bisexual Men in the HPTN 061 Study. J Acquir Immune Defic Syndr. 2018, 78: 491-498
E Greene, A Pack, J Stanton, V Shelus, EE Tolley, J Taylor, WM El-Sadr, BM Branson, J Leider, N Rakhmanina, T Gamble . "It Makes You Feel Like Someone Cares" Acceptability of a Financial Incentive Intervention for HIV Viral Suppression in the HPTN 065 (TLC-Plus) Study. PLoS One. 2017, 12: e0170686
EE Tolley, J Taylor, A Pack, E Greene, J Stanton, V Shelus, R Dunner, T Hodge, B Branson, WM El-Sadr, T Gamble . The Role of Financial Incentives Along the Antiretroviral Therapy Adherence Continuum: A Qualitative Sub-study of the HPTN 065 (TLC-Plus) Study. AIDS Behav. 2018, 22: 245-257
Eisenberg AL, Patel EU, Packman ZR, Fernandez RE, Piwowar-Manning E, Hamilton EL, MacPhail C, Hughes JP, Pettifor A, Kallas EG, Busch MP, Murphy G, Quinn TC, Eshleman SH, Laeyendecker O, for HPTN 068 and CEPHIA . Short Communication: Dried Blood Spots Stored at Room Temperature Should Not Be Used for HIV Incidence Testing. AIDS Res Hum Retroviruses. 2018, 34: 1013-1016
El-Diwany R, Breitwieser FP, Soliman M, Skaist AM, Srikrishna G, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A . Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals. AIDS. 2017, 31: 1405-1414
El-Sadr WM, Affrunti M, Gamble T, Zerbe A . , 55 Suppl 2: S116-21
El-Sadr WM, Affrunti M, Gamble T, Zerbe A . Antiretroviral therapy: a promising HIV prevention strategy?. J Acquir Immune Defic Syndr. 2010, 55: 116-21 PMCID: 3074403
El-Sadr WM, Beauchamp G, Hall IH, Torian LV, Zingman BS, Lum G, Elion RA, Buchacz K, Burns D, Zerbe A, Gamble T, Donnell D, for the HPTN 065 Study Team . Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care. JAIDS.
El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Masse B, Soto-Torres L, Kwiecien A and the HPTN 049 Team . Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006, 20: 1109-16 PMID: 16691061
El-Sadr WM, Serwadda DM, Sista N, Cohen MS . HIV prevention: great achievements, more challenges ahead. J Acquir Immune Defic Syndr. 2013, 63: S115-6
Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB . Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study). J Infect Dis. 2001, 184: 914-7
Eshleman SH, Church JD, Chen S, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Kumwenda N, Jackson JB, Taha TE, Hoover DR . Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006, 42: 518-21 PMID 16810119
Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J . Sensitivity and specificity of the ViroSeq® HIV-1 Genotyping System for detection of HIV-1 drug resistance mutations using an ABI PRISM® 3100 Genetic Analyzer. J Clin Micro. 2005, 43: 813-17 PMCID: 548107
Eshleman SH, Gonzales MJ, Becker-Pergola G, Cunningham SC, Guay LA, Jackson JB, Shafer RW . Identification of Ugandan HIV Type 1 Variants with Unique Patterns of Recombination in pol Involving Subtypes A and D. AIDS Res Hum Retroviruses. 2002, 18: 507-11
Eshleman SH, Guay LA, Fleming T, Mwatha A, Mracna M, Becker-Pergola G, Musoke, Mmiro F, Jackson JB . Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). J Acquir Immune Defic Syndr. 2002, 31: 327-30
Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, Mmiro F, Jackson JB . Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).. J Acquir Immune Defic Syndr. 2004, 35: 126-30
Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB . Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. 2004, 20: 595-99
Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, Mmiro F, Jackson JB . Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine: HIVNET 012. J Acquir Immune Defic Syndr. 2005, 40: 24-9
Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T . Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005, 192: 30-6
Eshleman SH, Hoover DR, Chen SH, Hudelson SH, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, and Taha T . Resistance after single dose nevirapine prophylaxis emerges in a high portion of Malawian newborns. AIDS. 2005, 19: 2167-68
Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning E, Jackson JB, Kumwenda NI, Taha T . Development of nevirapine resistance is reduced by using infant-only nevirapine plus zidovudine post-exposure prophylaxis to prevent HIV-1 mother–to-child transmission. J Infect Dis. 2006, 193: 479-81 PMID:16425125
Eshleman SH, Hudelson S, Gupta A, Bollinger R, Divekar AD, Gangakhedkar RR, Kulkarni SS, Thakar MR, Paranjape RS, and Tripathy S . Limited evolution in the HIV-1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses. 2005, 21: 93-97
Eshleman SH, Hudelson SE, Bruce R, Lee T, Owens MR, Hackett J, Swanson P, Devare SG, and Marlowe N . Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains. AIDS Res Hum Retroviruses. 2007, 23: 1593-8
Eshleman SH, Hudelson SE, Redd AD, Swanstrom R, Ou S-S, Zhang C, Ping L-H, Piwowar-Manning E, Porcella SF, Sievers MF, Martens CA, Bruno D, Dukhovlinova E, McCauley M, Gamble T, Fogel JM, Sabin D, Quinn TC, Gunde L, Maliwichi M, Nhando N, Akelo V, Moyo S, Panchia R, Kumarasamy N, Chotirosniramit N, Gonçalves de Melo M, Pilotto J, Grinsztejn B, Mayer K, Chen YQ, Hughes JP, Cohen MS . Treatment as Prevention: Characterization of partner infections in the HIV Prevention Trials Network 052 trial.. J Acquir Immune Defic Syndr. 2017, 74: 112-116
Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, Martens CA, Ricklefs SM, Selig EJ, Porcella SF, Munshaw S, Ray SC, Piwowar-Manning E, McCauley M, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, de Bruyn G, Grinsztejn B, et al . Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis. 2011, 204: 1918-26 PMCID: 3209811
Eshleman SH, Hudelson SE, Smith P, Hackett J, Holzmayer V, Swanson P, Devare SG, Marlowe N . Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses. 2009, 25: 343-5 PMCID: 2853838
Eshleman SH, Hughes JP, Laeyendecker O, Wang J, Brookmeyer R, Johnson-Lewis L, Mullis CE, Hackett J Jr, Vallari AS, Justman J, Hodder S . Use of a multi-faceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis. 2013, 207: 223-31
Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, Hart S, Jackson JB, Coates T, Chesney M, and Koblin B . Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS. 2007, 21: 1165-74 PMID: 17502727
Eshleman SH, Jackson JB . Nevirapine resistance after single dose prophylaxis. AIDS Reviews. 2002, 4: 59-63
Eshleman SH, Jones D, Flys T, Petrauskene O, and Jackson JB . Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping System. Biotechniques. 2003, 35: 614-8, 620, 622
Eshleman SH, Jones D, Galovich J, Paxinos EE, Petropoulos CJ, Jackson JB, Parkin N . Phenotypic Drug Resistance Patterns in Subtype A HIV-1 Clones with Nonnucleoside Reverse Transcriptase Resistance Mutations. AIDS Res Hum Retroviruses. 2006, 22: 289-93 PMID:16545016
Eshleman SH, Khaki L, Laeyendecker O, Piwowar-Manning E, Johnson-Lewis L, Husnik M, Koblin B, Coates T, Chesney M, Vallari A, Devare SG, Hackett J Jr . Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr. 2009, 52: 121-4 PMCID: 2744045
Eshleman SH, Laeyendecker O, Parkin N, Huang W, Chappey C, Paquet AC, Serwadda D, Reynolds SJ, Kiwanuka N, Quinn TC, Gray R, Wawer M . Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS. 2009, 27: 845-52 PMCID:2676205
Eshleman SH, Lie Y, Hoover DR, Chen S, Hudelson SE, Fiscus SA, Petropoulos CJ, Kumwenda N, Parkin N, and Taha TE . Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naïve Malawian women. J Infect Dis. 2006, 193: 1512-5 PMID:16652278
Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB . Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001, 15: 1951-7
Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, Godbole SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen YQ, Cohen MS, Fogel JM . Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017, 18: 100-109
Fatti G, Grimwood A, Nachega JB, Nelson JA, LaSorda K, Zyl GV, Grobbelaar N, Ayles H, Hayes R, Beyers N, Fidler S, Bock P, for the HPTN 071 Study Team . Better Virological Outcomes amongst People Living with HIV Initiating Early Antiretroviral Treatment (CD4 counts >/= 500 cells/microL) in the HPTN 071 (PopART) Trial in South Africa. Clin Infect Dis.
Fearon E, Wiggins RD, Pettifor AE, MacPhail C, Kahn K, Selin A, Gomez-Olive FX, Delany-Moretlwe S, Piwowar-Manning E, Laeyendecker O, Hargreaves JR . Associations between friendship characteristics and HIV and HSV-2 status amongst young South African women in the HPTN-068 study. J Int AIDS Soc. 2017, 20
Fearon E, Wiggins RD, Pettifor AE, MacPhail C, Kahn K, Selin A, Gomez-Olive FX, Hargreaves JR . Friendships Among Young South African Women, Sexual Behaviours and Connections to Sexual Partners (HPTN 068). AIDS Behav. 2019, 23: 1471-1483
Fiamma A, Lissouba P, Amy OE, Singh B, Laeyendecker O, Quinn TC, Taljaard D, Auvert B . Can HIV incidence testing be used for evaluating HIV intervention programs? A reanalysis of the Orange Farm male circumcision trial (ANRS-1265). BMC Infect Dis. 2010, 10: 137-46 PMCID: 2890001
Figueroa DB, Madeen EP, Tillotson J, Richardson P, Cottle L, McCauley M, Landovitz RJ, Andrade A, Hendrix CW, Mayer KH, Wilkin T, Gulick RM, Bumpus NN . Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses. 2018, 34: 421-429
Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN . Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN 067. PLoS One. 2018, 13: e0195764
Fleming TR, Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Grinsztejn B, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Pilotto JHS . Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016, 375: 830-9
Fleming TR, Richardson BA . Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis. 2004, 190: 666-74
Floyd S, Ayles H, Schaap A, Shanaube K, MacLeod D, Phiri M, Griffith S, Bock P, Beyers N, Fidler S, Hayes R, for the HPTN 071 Study Team . Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia. PLoS One. 2018, 13: e0197904
Flys T, Marlowe N, Hackett J, Parkin N, Schumaker M, Holzmayer V, Hay P, and Eshleman SH . Analysis of PTAP duplications in the gag p6 region of subtype C HIV-1. AIDS Res Hum Retroviruses. 2005, 21: 739-41
Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH . Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005, 192: 24-9
Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N, Taha TE, Jackson JB, Eshleman SH . Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006, 42: 610-13 PMID 16773030
Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH . Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007, 195: 711-5 PMID 17262714
Flys TS, McConnell MS, Matovu F, Church JD, Bagenda D, Khaki L, Bakaki P, Thigpen MC, Eure C, Fowler MG, Eshleman SH . Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis. 2008, 198: 465-9. PMCID:2640946
Flys TS, Mwatha A, Guay LA, Nakabiito C, Donnell D, Musoke P, Mmiro F, Jackson JB, and Eshleman SH . Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS. 2007, 21: 2077-82 PMID 17885298
Fogel J, Hoover DR, Sun J, Mofenson LM, Fowler MG, Taylor AW, Kumwenda N, Taha TE, Eshleman SH . Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS. 2011, 25: 911-17 PMCID: 3261770
Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, Kumwenda JJ, Fowler MG, Thigpen MT, Eshleman SH . Initiation of antiretroviral treatment in women after delivery can induce multi-class drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011, 52: 1069-76 PMCID: 3070029
Fogel JM, Clarke W, Kulich M, Piwowar-Manning E, Breaud A, Olson M, Marzinke M, Fiamma A, Donnell D, Mbwambo JKK, Richter L, Gray G, Sweat M, Coates TJ, Eshleman SH . Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043). J Acquir Immune Defic Syndr. 2018, 77: e48
Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar-Manning E, Sabin D, McCauley M, Gamble T, Zhang XC, Eron JJ, Gallant JE, Kumwenda J, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim J, Badal-Faesen S, Akelo V, Hosseinipour MC, Santos BR, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Mayer KH, Chen YQ, Cohen MS, Eshleman SH . HIV drug resistance in adults failing early antiretroviral treatment: results from the HIV Prevention Trials Network 052 trial. 2016, 72: 304-9
Fogel JM, Mwatha A, Richardson P, Brown ER, Chipato T, Alexandre M, Moodley D, Elbireer A, Mirochnick M, George K, Mofenson LM, Zwerski S, Coovadia HM, Eshleman SH . Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-Infected Breastfeeding Infants. Pediatr Infect Dis J. 2013, 32: e164-9
Fogel JM, Piwowar-Manning E, Debevec B, Walsky T, Schlusser K, Laeyendecker O, Wilson EA, McCauley M, Gamble T, Tegha G, Soko D, Kumwenda J, Hosseinipour MC, Chen YQ, Cohen MS, Eshleman SH . Impact of early antiretroviral therapy on the performance of HIV rapid tests and HIV incidence assays. J Acquir Immune Defic Syndr. 2017, 75: 426-430
Fogel JM, Piwowar-Manning E, Donohue K, Cummings V, Marzinke MA, Clarke W, Breaud A, Fiamma A, Donnell D, Kulich M, Mbwambo JK, Richter L, Gray G, Sweat M, Coates TJ, Eshleman SH . Determination of HIV Status in African Adults With Discordant HIV Rapid Tests. J Acquir Immune Defic Syndr. 2015, 69: 430-8
Fogel JM, Sandfort T, Zhang Y, Guo X, Clarke W, Breaud A, Cummings V, Hamilton EL, Ogendo A, Kayange N, Panchia R, Dominguez K, Chen YQ, Eshleman SH . Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. AIDS Behav. 2019, 23: 289-294
Fogel JM, Sivay MV, Cummings V, Wilson EA, Hart S, Gamble T, Laeyendecker O, Fernandez RE, Del Rio C, Batey D S, Mayer KH, Farley JE, McKinstry L, Hughes JP, Remien RH, Beyrer C, Eshleman SH . HIV Drug Resistance in a Cohort of HIV-Infected Men Who Have Sex with Men in the United States. AIDS. 2019
Fogel JM, Taha TE, Sun J, Hoover DR, Parsons TL, Kumwenda JJ, Mofenson LM, Fowler MG, Hendrix CW, Kumwenda NI, Eshleman SH, Mirochnick M . Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants. J Acquir Immune Defic Syndr. 2012, 60: 462-5 PMCID: 3404155
Fogel JM, Wang L, Parsons TL, Ou SS, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, Panchia R, Kumarasamy N, Grinsztejn B, Makhema J, Pilotto J, Santos BR, Mayer KH, McCauley M, Gamble T, et. Al, Bumpus N, Hendrix C, Cohen M, Eshleman S . Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013, 208: 1624-8